Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

The New England journal of medicine·2026
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026
Same author

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

American journal of hematology·2026

Related Experiment Video

Updated: Oct 4, 2025

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.9K

Current approach to Waldenström Macroglobulinemia.

Gayathri Ravi1, Prashant Kapoor1

  • 1Division of Hematology Mayo Clinic, Rochester, MN, United States of America.

Cancer Treatment and Research Communications
|February 12, 2022
PubMed
Summary

Waldenström Macroglobulinemia (WM) treatment choices are complex. This review clarifies diagnosis, prognosis, and therapy options, including Bruton's tyrosine kinase (BTK) inhibitors and chemo-immunotherapy, based on patient mutation status.

Keywords:
Anti CD20 monoclonal antibodiesBTK inhibitorsChemoimmunotherapyIgM lymphoplasmacytic lymphoma

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K

Related Experiment Videos

Last Updated: Oct 4, 2025

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.9K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Waldenström Macroglobulinemia (WM) is a rare IgM lymphoplasmacytic lymphoma with variable clinical behavior.
  • Limited high-quality evidence from Phase 3 trials complicates treatment decisions despite new therapies.
  • MYD88 and CXCR4 mutation status influences treatment selection for WM patients.

Purpose of the Study:

  • To review current literature on Waldenström Macroglobulinemia diagnosis, prognosis, and treatment.
  • To discuss therapeutic strategies considering patient-specific genetic markers.
  • To compare fixed-duration chemo-immunotherapy versus indefinite Bruton's tyrosine kinase (BTK) inhibitor regimens.

Main Methods:

  • Comprehensive literature review of WM diagnosis, prognosis, and treatment.
  • Analysis of therapeutic options including bendamustine-rituximab (BR) and BTK inhibitors.
  • Evaluation of treatment efficacy based on MYD88 and CXCR4 mutation status.

Main Results:

  • MYD88 L265P and CXCR4 mutation status guides BTK inhibitor therapy decisions.
  • Bendamustine-rituximab (BR) is preferred for MYD88 WT WM, while BTK inhibitors are effective for MYD88 L265P WM.
  • Zanubrutinib shows activity in MYD88 WT WM, offering an alternative to chemo-immunotherapy.

Conclusions:

  • Optimal treatment selection for WM requires consideration of genetic mutations (MYD88, CXCR4).
  • Both BR and BTK inhibitor regimens are effective and well-tolerated, particularly for MYD88 L265P patients.
  • Further comparative data is needed to definitively guide treatment choices between different regimens.